Objetives : The purpose of this study was to examine the pathway of anti-allergic effects of Aconiti Ciliare Tuber (ACT). Methods : We examined cell viability, ${eta}$-hexosaminidase release, pro-inflammatory cytokines secretion and mRNA expressions, nuclear factor-kappa B (NF-${kappa}B$) (p65) activation, inhibitor kappa B-alpha ($I{kappa}B-{alpha}$) degradation, and MAPKs activation from RBL-2H3 cells pre-treatment by ACT of 1.0 mg/ml, 2.0 mg/ml separately. Results : We observed that ACT reduced the secretion of ${eta}$-hexosaminidase, TNF-${alpha}$, IL-4 and the expression of COX-2 mRNA in RBL-2H3 cells. Futhermore, ACT inhibited the levels of activation of NF-${kappa}B$ (p65) protein, ERK MAPK, and degradation of $I{kappa}B-{alpha}$ in RBL-2H3 cells. Conclusions : These results show that ACT has an anti-histamine effect and inhibitory effect of NF-${kappa}B$ (p65) through regulation of $I{kappa}B-{alpha}$ degradation. This improves that ACT could be used as an anti-allergic medicine.